Defining the possibilities: Is short duration treatment of chronic hepatitis C genotype 1 with sofosbuvir-containing regimens likely to be as effective as current regimens?

Expert Review of Anti-Infective Therapy

Volumn 14, Issue 1, 2016, Pages 41-56

  Nafisi, Shirin ^a   Roy, Sabyasachi ^a   Gish, Robert ^a   Manch, Richard ^a   Kohli, Anita ^a  

^a ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

(5 10): sofosbuvir; Directly acting antivirals; Duration; Genotype 1; Hepatitis C; IFN free regimens; NS5B inhibitor

Indexed keywords

ANTIVIRUS AGENT; DACLATASVIR; ELBASVIR; GRAZOPREVIR; GS 9857; LEDIPASVIR; ODALASVIR; RADALBUVIR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; UNCLASSIFIED DRUG; VEDROPREVIR; VELPATASVIR; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; VIRUS RNA;

CHRONIC HEPATITIS C; CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG RESPONSE; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; COMBINATION DRUG THERAPY; COMPLICATION; DISEASE MANAGEMENT; DRUG ADMINISTRATION; DRUG EFFECTS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; PATHOGENICITY; PHYSIOLOGY; TIME FACTOR; VIROLOGY; VIRUS LOAD;

ANTIVIRAL AGENTS; BENZIMIDAZOLES; DISEASE MANAGEMENT; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FLUORENES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; RIBAVIRIN; RNA, VIRAL; SOFOSBUVIR; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84954403189     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2016.1114883     Document Type: Review

References (31)

1. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879-1888
2. Kohli A, Shaffer A, Sherman A, et al. Treatment of hepatitis C: a systematic review. JAMA. 2014;312:631-640
3. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. [Internet]. [cited 2015 Jul 17]. Available from: http://hcvguidelines. org/full-report/website-policies.)
4. Peterson T, Gordon L, Townsend K, et al. Pill Burdern and Treatment Duration Reduce Adherence to IFN-Free Hepatitis C Therapy in an Urban Cohort. Conference on Retroviruses and Opportunistic Infections 2014
5. Kohli A, Osinusi A, Sims Z, et al. Virological response after 6 week tripledrug regimens for hepatitis C: a proof-ofconcept phase 2A cohort study. Lancet. 2015;385:1107-1113.
6. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889-1898
7. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483-1493
8. Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. The Lancet. 2014;383:515-523
9. Osinusi A, Meissner EG, Lee YJ, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. Jama. 2013;310:804-811.
10. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013;368:34-44
11. Tran T, Morgan T, Thuluvath PJ, et al. Safety and Efficacy of Treatment with Sofosbuvir + GS-5816 Ribavirin for 8 or 12 weeks in Treatment Naive Patients with Genotype 1-6 HCV Infection. American Association for the Study of Liver Diseases Meeting 2014
12. Pianko S, Flamm S, Shiffman ML, et al. High Efficacy of Treatment with Sofosbuvir + GS-5816 +/-Ribavirin for 12 weeks in Treatment Experienced Patients with Genotype 1 or 3 HCV Infection. American Association for the Study of Liver Diseases Meeting 2014
13. Poordad FF, Lawitz E, Gutierrez JA, et al. C-SWIFT: Grazoprevir/Elbasvir + Sofosbuvir in Cirrhotic and Non-Cirrhotic, Treatment-Naive Patients with Hepatitis C Virus Genotype 1 Infection, for Durations of 4, 6, or 8 weeks and Genotype 3 Infection for Durations of 8 or 12 weeks. European Association for the Study of the Liver Meeting 2015.
14. Gane EJ, Hyland RH, Ying Y, et al. Safety and Efficacy of Short-Duration Treatment with GS-9857 Combined with Sofosbuvir/GS-5816 in Treatment-Naive and DAA-Experienced Genotype 1 Patients With and Without Cirrhosis. European Association for the Study of the Liver Meeting 2015.
15. Lawitz E, Matusow G, DeJesus E, et al. A Phase 3, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of 12 Weeks of Simeprevir (SMV) Plus Sofosbuvir (SOF) in Treatment-Naive or-Experienced Patients with Chronic HCV Genotype 1 Infection and Cirrhosis: OPTIMIST-2. European Association for the Study of the Liver Meeting 2015
16. Gane EJ, Schwabe C, Mader M, et al. Sustained Virologic Response After ACH-3102 and Sofosbuvir Treatment for 8 or 6 Weeks: A Phase 2 "PROXY" Study. European Association for the Study of the Liver Meeting 2015
17. Kwo P, Gitlin N, Nahass R, et al. A Phase 3, Randomised, Open-Label Study to Evaluate the Efficacy and Safety of 8 and 12 Weeks of Simeprevir (SMV) Plus Sofosbuvir (SOF) in Treatment-Naive and-Experienced Patients with Chronic HCV Genotype 1 Infection Without Cirrhosis: OPTIMIST-1. European Association for the Study of the Liver Meeting 2015
18. Lim YS, Chuang WL, Ahn SH, et al. 98% SVR12 in Korean and Taiwanese Patients With Chronic Genotype 1 HCV Infection Receiving 12 Weeks of Ledipasvir/Sofosbuvir: Results From An International Multicenter Phase 3 Study. European Association for the Study of the Liver Meeting 2015
19. Kattakuzhy S, Sidharthan S, Wilson E, et al. Predictors of Sustained Viral Response to 4-6 Week Duration Therapy With Ledipasvir + Sofosbuvir + GS-9451 +/-GS-9669 in Early and Advanced Fibrosis (NIH/UMD SYNERGY Trial). European Association for the Study of the Liver Meeting 2015
20. Lalezari J, Nelson DR, Hyland RH, et al. Once Daily Sofosbuvir Plus Ribavirin For 12 and 24 Weeks in Treatment-Naive Patients with HCV Infection: The Quantum Study. European Association for the Study of the Liver Meeting 2013
21. Lawitz E, Poordad FF, Hyland RH, et al. High Rates of SVR in Patients with Genotype 1 HCV Infection and Cirrhosis After Treatment with Ledipasvir/ Sofosbuvir + Ribavirin or Ledipasvir/ Sofosbuvir + GS-9669 for 8 Weeks. American Association for the Study of Liver Diseases 2014
22. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211-221
23. Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis. 2015;15:645-653
24. Bourliere M, Bronowicki JP, De Ledinghen V, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis. 2015;15:397-404
25. Pearlman BL, Ehleben C, Perrys M. The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis. Gastroenterology. 2015;148:762-70 e2. quiz e11-2
26. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in nonresponders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384:1756-1765
27. Gane EJ, Stedman CA, Hyland RH, et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology. 2014;146:736-43 e1
28. Lawitz E, Poordad FF, Gutierrez JA, et al. C-Swift: grazoprevir (MK-5172) + Elbasvir (MK-85472) + Sofosbuvir in Treatment Naive Patients with Hepatitis C Virus Genoytpe 1 Infection, With and Without Virrhosis, for Durations of 4, 6 or 8 Weeks (Interim Results). American Association for the Study of Liver Diseases 2014;Boston
29. Ferenci P. Predictors of response to therapy for chronic hepatitis C. Semin Liver Dis. 2004;24(Suppl 2):25-31
30. Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med. 2015;163:1-13
31. Forns X, Gordon SC, Zuckerman E, et al. Grazoprevir/Elbasvir plus Ribavirin For Chronic HCV Genotype-1 Infection After Failure of Combination Therapy Containing a Direct-Acting Antiviral Agent. J Hepatol. 2015;63(3):564-572.